** U.S.-listed shares of psychedelics-based drug developer atai Life Sciences 9VC.F, ATAI.O rise 11.7% to $1.53 premarket
** President-elect Donald Trump selects Robert F. Kennedy Jr. to lead the Department of Health and Human Services
** Kennedy has previously criticized the U.S. FDA over its "aggressive suppression" of psychedelics
** ATAI has several drugs in development that are based on psychedelic drugs, including VLS-01 for treatment-resistant depression that is a formulation of dimethyltryptamine, or DMT, and EMP-01 for social anxiety disorder that uses a form of MDMA
** "RFK Jr seems positively inclined and sounds motivated to help foster psychedelic drug development," and appears to recognize "responsible" use of MDMA, Jefferies analyst Andrew Tsai said in a note on Monday
** Brokerage notes programs from cos such as ATAI, Compass Pathways CMPS.O and GH Research GHRS.O that are using pyschedelic-based drugs
** Up to last close, ATAI shares had fallen 2.8% YTD versus a 5.4% increase in the Nasdaq Biotechnology index .NBI
(Reporting by Leroy Leo in Bengaluru)
((Leroy.Dsouza@thomsonreuters.com))
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。